Breaking News

Celerion To Support FNIH Biomarkers Consortium

June 11, 2014

Will provide clinical services to support The Beta Cell Project

Celerion has been selected by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium to provide clinical support for The Beta Cell Project, a program of studies designed to standardize biomarker measures of beta cell function. Celerion will provide clinical services to support the development of pharmacodynamic measures with the goal of creating industry standards.
 
The Biomarkers Consortium is a public-private biomedical research partnership managed by the FNIH aims to discover, develop, and qualify biomarkers to support drug development, preventive medicine, and medical diagnostics. 
 
“Celerion has continued to invest in and expand our capabilities in metabolic disease to support early Proof-of-Concept studies in the development of diabetes, obesity, metabolic and cardio-metabolic interventions. We are therefore delighted to have been selected to support programs by the FNIH in the area of metabolic disorders,” said Philip Bach, vice president of Global Clinical Research at Celerion. “The award of this program, and knowing that our contribution will help set industry standards, is recognition of our expertise in this area and the quality of data delivered to clients.”
  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems